CN117599012A - Preparation method of nose comfort tablet - Google Patents
Preparation method of nose comfort tablet Download PDFInfo
- Publication number
- CN117599012A CN117599012A CN202311682556.9A CN202311682556A CN117599012A CN 117599012 A CN117599012 A CN 117599012A CN 202311682556 A CN202311682556 A CN 202311682556A CN 117599012 A CN117599012 A CN 117599012A
- Authority
- CN
- China
- Prior art keywords
- powder
- cum bile
- arisaema cum
- mixing
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 32
- 210000000941 bile Anatomy 0.000 claims abstract description 24
- 238000002156 mixing Methods 0.000 claims abstract description 24
- 241000489492 Arisaema Species 0.000 claims abstract description 23
- 238000000605 extraction Methods 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 14
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims abstract description 12
- 229940046978 chlorpheniramine maleate Drugs 0.000 claims abstract description 12
- 230000002195 synergetic effect Effects 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 9
- 229920002472 Starch Polymers 0.000 claims abstract description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 7
- 235000019698 starch Nutrition 0.000 claims abstract description 7
- 239000008107 starch Substances 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims abstract description 3
- 238000007873 sieving Methods 0.000 claims description 10
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 claims description 8
- 241000213006 Angelica dahurica Species 0.000 claims description 8
- 241000928504 Centipeda minima Species 0.000 claims description 8
- 244000035851 Chrysanthemum leucanthemum Species 0.000 claims description 8
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims description 8
- 244000286838 Eclipta prostrata Species 0.000 claims description 8
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 8
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 8
- 241000159213 Zygophyllaceae Species 0.000 claims description 8
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 8
- 235000011477 liquorice Nutrition 0.000 claims description 8
- 235000009165 saligot Nutrition 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 6
- 235000019477 peppermint oil Nutrition 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 239000001738 pogostemon cablin oil Substances 0.000 claims description 5
- 244000236658 Paeonia lactiflora Species 0.000 claims description 4
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims 2
- 244000067505 Xanthium strumarium Species 0.000 claims 1
- 235000011803 sesame oil Nutrition 0.000 claims 1
- 239000008159 sesame oil Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 239000004480 active ingredient Substances 0.000 abstract description 6
- 238000000227 grinding Methods 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 3
- 238000003908 quality control method Methods 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 241000628997 Flos Species 0.000 abstract description 2
- 239000009670 cang er zi wan Substances 0.000 abstract description 2
- 238000004090 dissolution Methods 0.000 abstract description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 abstract description 2
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 238000009495 sugar coating Methods 0.000 abstract 1
- 239000008187 granular material Substances 0.000 description 12
- 206010039083 rhinitis Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 210000001331 nose Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 4
- 206010028748 Nasal obstruction Diseases 0.000 description 4
- 206010039101 Rhinorrhoea Diseases 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 208000010753 nasal discharge Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241001506766 Xanthium Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 201000009151 chronic rhinitis Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001944 turbinate Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a preparation method of a nose comfort tablet, which comprises the following steps: mixing fructus Xanthii, flos Chrysanthemi Indici, herba Centipedae, radix Angelicae Dahuricae, radix Saposhnikoviae, herba Ecliptae, radix Paeoniae alba, glycyrrhrizae radix and fructus Tribuli, pulverizing, micronizing to obtain second powder, mixing with water, extracting in a microwave and ultrasonic synergistic extraction tank, filtering, and concentrating to obtain soft extract; adding Arisaema cum bile fine powder and medicinal starch, granulating, drying, adding chlorpheniramine maleate, magnesium stearate, oleum herba Pogostemonis, and oleum Menthae Dementholatum, tabletting, and sugar coating. The preparation method adopts superfine grinding to treat the raw materials, and combines microwave-ultrasonic synergistic extraction to facilitate the full dissolution of active ingredients, avoid the damage of high temperature to the active ingredients, and the prepared nasal comfort tablet has high curative effect. Moreover, the method is simple to operate, is suitable for quality control, is convenient for industrial production, and has good application prospect.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a preparation method of a nose comfort tablet.
Background
It is reported that one sixth of people worldwide suffer from various rhinitis, and domestic rhinitis incidence is far higher than this data. Rhinitis is a common disease, namely, nasal inflammatory disease, is inflammation of nasal mucosa caused by viruses, bacteria, allergens, various physical and chemical factors and certain systemic diseases, the main pathological changes of rhinitis are congestion, swelling, exudation, hyperplasia, atrophy or necrosis of nasal mucosa, and the like, especially in the days of increasingly serious environmental pollution and increasingly severe extreme weather with ever-changing changes, rhinitis patients are more and less aged, the rhinitis looks like small diseases and is very harmful, the five sense organs of a human body are greatly influenced in the onset period, great pain is brought to the work and life of the rhinitis patients, and a plurality of serious diseases are induced even endangered by the fact that effective treatment is not available for a long time.
And the nose comfort tablet is stored in a seventh book of standard Chinese medicine prescription preparation of the ministry of health. Is prepared from fructus Xanthii, flos Chrysanthemi Indici, herba Centipedae, radix Angelicae Dahuricae, radix Saposhnikoviae, herba Ecliptae, radix Paeoniae alba, rhizoma arisaematis cum bile, glycyrrhrizae radix, fructus Tribuli, and chlorpheniramine maleate. The nasal comforting tablet has effects of clearing heat, relieving inflammation, and inducing resuscitation, and can be used for treating sneeze, watery nasal discharge, nasal obstruction, headache, allergic rhinitis, and chronic sinusitis caused by chronic rhinitis. And the use is convenient, and the market prospect is extremely wide.
However, the existing production process of the nose comfort tablet is quite a lot, so that the quality of the nose comfort tablet is uneven, and in addition, the nose comfort tablet is prepared by adopting the traditional process, and has the defects of low curative effect and the like. Thus, there is a need for an improved process for preparing nasal comfort tablets.
Disclosure of Invention
In view of the defects of the prior art, the technical problem to be solved by the invention is to provide a preparation method of the nose comfort tablet, which adopts superfine grinding to treat raw materials, combines microwave-ultrasonic synergistic extraction, is beneficial to fully dissolving out active ingredients, avoids damaging the active ingredients at high temperature, and has high curative effect.
In order to achieve the purpose of the invention, the invention adopts the following technical scheme:
the invention provides a preparation method of a nose comfort tablet, which comprises the following steps:
(1) Weighing 364g of fructus xanthil, 145g of wild chrysanthemum, 218g of centipeda minima, 109g of angelica dahurica, 109g of radix sileris, 218g of eclipta alba, 145g of white peony root, 70g of arisaema cum bile, 73g of liquorice, 218g of caltrop and 0.3g of chlorpheniramine maleate for later use;
(2) Crushing the arisaema cum bile weighed in the step (1), and sieving the crushed arisaema cum bile by a 80-100-mesh sieve to obtain arisaema cum bile fine powder;
(3) Mixing the cocklebur fruit, the wild chrysanthemum flower, the centipeda minima, the angelica dahurica, the radix sileris, the eclipta alba, the liquorice and the caltrop which are weighed in the step (1), crushing for 1-2 hours by adopting a crusher to obtain first powder, and then putting the first powder into an ultrafine crusher to crush for 0.5-1 hour to obtain second powder;
(4) Adding water into the second powder prepared in the step (3) for mixing, then adding the mixture into a microwave and ultrasonic synergistic extraction tank for extraction, and filtering and concentrating the extract to obtain thick paste;
(5) Adding the arisaema cum bile fine powder obtained in the step (4) into the thick paste obtained in the step (2), adding a proper amount of auxiliary material medical starch, uniformly mixing, granulating, drying, adding chlorpheniramine maleate and a proper amount of magnesium stearate, patchouli oil and peppermint oil which are weighed in the step (1), uniformly mixing, tabletting, and coating with sugar to obtain the nasal comfort tablet.
Preferably, in step (4):
the volume ratio of the second powder to the water is 1:4-6.
The ultrasonic frequency is 30-40KHz, and the power is 0.8-1KW; the microwave frequency is 1500-1600MHz, and the power is 2-2.5KW; the synergistic extraction temperature is 55-65deg.C, and the extraction time is 1.5-2.5 hr.
The concentration adopts a vacuum concentration tank, and the vacuum degree is controlled to be 0.04-0.06 Mpa in the concentration process.
Preferably, in step (5):
adding Arisaema cum bile fine powder obtained in the step (4) into the thick paste obtained in the step (2), adding a proper amount of medicinal starch serving as an auxiliary material, uniformly mixing in a groove type mixer, adding a swing type granulator, sieving with a 12-mesh sieve to prepare wet granules, then adding a one-step granulator, drying for 30-45 minutes, controlling the temperature at 50-60 ℃ to enable the moisture of the granules to be within 5%, stopping drying, pouring out, adding a swing type granulator, sieving with a 14-mesh sieve to prepare granules, finally adding the prepared granules into a total mixing device, adding chlorpheniramine maleate weighed in the step (1) and a proper amount of magnesium stearate, patchouli oil and peppermint oil, uniformly mixing, tabletting, and coating sugar to obtain the nasal comfort tablet.
Compared with the prior art, the invention has the following beneficial effects:
the invention provides a preparation method of a nose comfort tablet, which adopts superfine grinding to treat raw materials, combines microwave-ultrasonic synergistic extraction to be beneficial to the full dissolution of active ingredients, avoids the damage of high temperature to the active ingredients, and has high curative effect, thereby reducing the dosage of oral administration and reducing the side effect of oral administration medicine to human liver. Moreover, the method is simple to operate, is suitable for quality control, is convenient for industrial production, and has good application prospect.
Detailed Description
The following detailed description of the embodiments of the present invention is provided for better illustration of the present invention, but is not to be construed as limiting the invention.
The specific techniques or conditions are not identified in the examples and are described in the literature in this field or are carried out in accordance with the product specifications. The reagents or equipment used were conventional products available for purchase through regular channels, with no manufacturer noted.
Example 1: a method of preparing a nasal comfort tablet comprising:
(1) Weighing 364g of fructus xanthil, 145g of wild chrysanthemum flower, 218g of centipeda minima, 109g of angelica dahurica, 109g of radix sileris, 218g of eclipta alba, 145g of white peony root, 70g of arisaema cum bile, 73g of liquorice, 218g of caltrop and 0.3g of chlorpheniramine maleate;
(2) Crushing the arisaema cum bile weighed in the step (1), and sieving the crushed arisaema cum bile with a 80-mesh sieve to obtain arisaema cum bile fine powder;
(3) Mixing the cocklebur fruit, the wild chrysanthemum flower, the centipeda minima, the angelica dahurica, the radix sileris, the eclipta alba, the liquorice and the caltrop which are weighed in the step (1), crushing for 1h by adopting a crusher to obtain first powder, and then placing the first powder into a superfine crusher to crush for 0.5h to obtain second powder;
(4) Adding water with the volume being 4 times that of the second powder prepared in the step (3), stirring and mixing, then adding the second powder into a microwave and ultrasonic wave synergistic extraction tank for extraction, wherein the ultrasonic frequency is 30KHz, and the power is 0.8KW; the microwave frequency is 1500MHz, and the power is 2KW; the synergic extraction temperature is 55 ℃, and the extraction time is 1.5h; filtering the obtained extracting solution, concentrating the filtrate by adopting a vacuum concentration tank, controlling the vacuum degree to be 0.04Mpa, and preparing thick paste when the extracting solution is concentrated to the density of 1.30-1.35;
(5) Adding Arisaema cum bile fine powder obtained in the step (4) into the thick paste obtained in the step (2), adding a proper amount of auxiliary material medicinal starch, uniformly mixing in a groove type mixer, adding a swing type granulator, sieving with a 12-mesh sieve to prepare wet granules, then placing into a one-step granulator for drying for 30 minutes, controlling the temperature at 50 ℃ to control the water content of the granules to be within 5%, stopping drying, pouring out, placing into a swing type granulator, sieving with a 14-mesh sieve to obtain granules, finally putting the prepared granules into a total mixing device, adding chlorpheniramine maleate weighed in the step (1) and a proper amount of magnesium stearate, 0.5ml of patchouli oil and 0.5ml of peppermint oil, uniformly mixing, tabletting, and coating sugar to obtain 1000 nasal comfort tablets (0.2 g each tablet).
Example 2: a method of preparing a nasal comfort tablet comprising:
(1) Weighing 364g of fructus xanthil, 145g of wild chrysanthemum flower, 218g of centipeda minima, 109g of angelica dahurica, 109g of radix sileris, 218g of eclipta alba, 145g of white peony root, 70g of arisaema cum bile, 73g of liquorice, 218g of caltrop and 0.3g of chlorpheniramine maleate;
(2) Crushing the arisaema cum bile weighed in the step (1), and sieving the crushed arisaema cum bile by a 100-mesh sieve to obtain arisaema cum bile fine powder;
(3) Mixing the cocklebur fruit, the wild chrysanthemum flower, the centipeda minima, the angelica dahurica, the radix sileris, the eclipta alba, the liquorice and the caltrop which are weighed in the step (1), crushing the mixture for 2 hours by a crusher to obtain first powder, and then placing the first powder into a superfine crusher to crush for 1 hour to obtain second powder;
(4) Adding water with the volume being 4 times that of the second powder prepared in the step (3), stirring and mixing, and then adding the second powder into a microwave and ultrasonic wave synergistic extraction tank for extraction, wherein the ultrasonic wave frequency is 40KHz, and the power is 1KW; the microwave frequency is 1600MHz, and the power is 2.5KW; the synergistic extraction temperature is 65 ℃ and the extraction time is 2.5h; filtering the obtained extracting solution, concentrating the filtrate by adopting a vacuum concentration tank, controlling the vacuum degree to be 0.06Mpa, and preparing thick paste when the extracting solution is concentrated to the density of 1.30-1.35;
(5) Adding Arisaema cum bile fine powder obtained in the step (4) into the thick paste obtained in the step (2), adding a proper amount of auxiliary material medicinal starch, uniformly mixing in a groove type mixer, adding a swing type granulator, sieving with a 12-mesh sieve to prepare wet granules, then placing into a one-step granulator for drying for 45 minutes, controlling the temperature to be 60 ℃ so that the water content of the granules is controlled to be within 5%, stopping drying, pouring out, placing into a swing type granulator, sieving with a 14-mesh sieve to prepare granules, finally putting the prepared granules into a total mixing device, adding chlorpheniramine maleate weighed in the step (1) and a proper amount of magnesium stearate, 0.5ml of patchouli oil and 0.5ml of peppermint oil, uniformly mixing, tabletting, and coating sugar to obtain 1000 nasal comfort tablets (0.2 g each tablet).
Clinical trials
1. Diagnostic criteria for traditional Chinese medicine
The traditional Chinese medicine diagnosis and treatment standard of the traditional Chinese medicine disease is referred to the traditional Chinese medicine industry standard of the people's republic of China issued by the national traditional Chinese medicine administration.
2. Study object
The experimental cases are selected from 90 cases of chronic rhinitis patients which are diagnosed at the clinic of otorhinolaryngology department, are 20-60 years old and meet the diagnosis standard, and are randomly divided into 3 groups.
3. Research method
Treatment group 1: the nasal comforting tablet prepared in example 1 was orally taken 3 times a day, 4 tablets at a time, and 7 days as a course of treatment, followed by 2 courses of treatment.
Treatment group 2: the nasal comforting tablet prepared in example 2 was orally taken 3 times a day, 4 tablets at a time, and 7 days as a course of treatment, followed by 2 courses of treatment.
Control group: the nasal comfort tablet of the new peak pharmaceutical industry is orally taken 3 times a day, 4 tablets at a time, 7 days is a treatment course, and 2 treatment courses are continuously taken.
No other therapeutic agents or methods were used throughout the treatment, and observations and evaluations were made on days 1, 7, 9, 12, 14 of the treatment. The results are shown in Table 1.
The symptoms were observed: sneeze, nasal discharge, nasal obstruction, headache, turbinate swelling, mucous membrane and nasal secretion, tongue and pulse.
Clinical efficacy assessment criteria
(1) And (3) curing: symptoms such as sneeze, nasal obstruction, watery nasal discharge, headache and the like disappear, and the nasal cavity is checked to be normal, and the score is 0.
(2) The effect is shown: the sign of the main symptoms is obviously improved (50-70%), and the integral is reduced by 2/3.
(3) The method is effective: the symptoms of sneeze, nasal obstruction, nasal discharge, headache and the like are reduced, the local physical signs are obviously improved, and the integral is reduced by 1/3.
(4) Invalidation: no significant improvement in symptoms and signs, no change in integration.
Table 1: therapeutic effect of nasal comfort tablets
As can be seen from Table 1, the nasal comfort tablet prepared by the preparation method has obvious treatment effect on chronic rhinitis, and the treatment effect is obviously higher than that of the existing commercial nasal comfort tablet. The preparation method is simple to operate, is suitable for quality control, is convenient for industrial production, and has good application prospect.
It is apparent that the above examples are only illustrative of the present invention and are not limiting of the embodiments of the present invention. Various modifications and alterations of this invention may be made by those skilled in the art without departing from the spirit and scope of this invention. Thus, it is intended that the present invention also include such modifications and alterations insofar as they come within the scope of the appended claims or the equivalents thereof.
Claims (5)
1. A method of preparing a nasal comfort tablet, the method comprising:
(1) Weighing 364g of fructus xanthil, 145g of wild chrysanthemum, 218g of centipeda minima, 109g of angelica dahurica, 109g of radix sileris, 218g of eclipta alba, 145g of white peony root, 70g of arisaema cum bile, 73g of liquorice, 218g of caltrop and 0.3g of chlorpheniramine maleate for later use;
(2) Crushing the arisaema cum bile weighed in the step (1), and sieving the crushed arisaema cum bile by a 80-100-mesh sieve to obtain arisaema cum bile fine powder;
(3) Mixing the cocklebur fruit, the wild chrysanthemum flower, the centipeda minima, the angelica dahurica, the radix sileris, the eclipta alba, the liquorice and the caltrop which are weighed in the step (1), crushing for 1-2 hours by adopting a crusher to obtain first powder, and then putting the first powder into an ultrafine crusher to crush for 0.5-1 hour to obtain second powder;
(4) Adding water into the second powder prepared in the step (3) for mixing, then adding the mixture into a microwave and ultrasonic synergistic extraction tank for extraction, and filtering and concentrating the extract to obtain thick paste;
(5) Adding the arisaema cum bile fine powder obtained in the step (4) into the thick paste obtained in the step (2), adding a proper amount of auxiliary material medical starch, uniformly mixing, granulating, drying, adding chlorpheniramine maleate and a proper amount of magnesium stearate, patchouli oil and peppermint oil which are weighed in the step (1), uniformly mixing, tabletting, and coating with sugar to obtain the nasal comfort tablet.
2. The method according to claim 1, wherein in the step (4), the volume ratio of the second powder to water is 1:4-6.
3. The method according to claim 1, wherein in the step (4), the ultrasonic frequency is 30-40KHz and the power is 0.8-1KW; the microwave frequency is 1500-1600MHz, and the power is 2-2.5KW; the synergistic extraction temperature is 55-65 ℃; the extraction time is 1.5-2.5h.
4. The method according to claim 1, wherein in the step (4), the concentration is performed in a vacuum concentration tank, and the vacuum degree is controlled to be 0.04-0.06 Mpa during the concentration.
5. The preparation method of claim 1, wherein in the step (5), the arisaema cum bile fine powder of the step (2) is added into the thick paste prepared in the step (4), then a proper amount of auxiliary material medical starch is added, the mixture is uniformly mixed in a groove type mixer, then the mixture is put into a swing type granulator to be wet through a 12-mesh sieve, the mixture is put into a one-step granulator to be dried for 30 to 45 minutes, the temperature is controlled to be 50 to 60 ℃ to ensure that the water content of the particles is controlled to be within 5 percent, the mixture is stopped to be dried, poured out, put into a swing type granulator to be sieved through a 14-mesh sieve for finishing, and finally the prepared particles are put into a total mixing device, and then the chlorpheniramine maleate weighed in the step (1) and a proper amount of magnesium stearate, the sesame oil and the peppermint oil are added, uniformly mixed, pressed into tablets and sugar-coated to obtain the nose comfort tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311682556.9A CN117599012A (en) | 2023-12-08 | 2023-12-08 | Preparation method of nose comfort tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311682556.9A CN117599012A (en) | 2023-12-08 | 2023-12-08 | Preparation method of nose comfort tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117599012A true CN117599012A (en) | 2024-02-27 |
Family
ID=89947996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311682556.9A Pending CN117599012A (en) | 2023-12-08 | 2023-12-08 | Preparation method of nose comfort tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117599012A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102988480A (en) * | 2012-10-08 | 2013-03-27 | 卞毓平 | Method for preparing bile and patchouli rhinitis tablets and application |
| CN104983967A (en) * | 2015-06-18 | 2015-10-21 | 南京华宽信息咨询中心 | Preparation method and application of nasal comforting tablets |
| CN113940957A (en) * | 2021-12-02 | 2022-01-18 | 张鹏 | Formula for treating rhinitis disease |
-
2023
- 2023-12-08 CN CN202311682556.9A patent/CN117599012A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102988480A (en) * | 2012-10-08 | 2013-03-27 | 卞毓平 | Method for preparing bile and patchouli rhinitis tablets and application |
| CN104983967A (en) * | 2015-06-18 | 2015-10-21 | 南京华宽信息咨询中心 | Preparation method and application of nasal comforting tablets |
| CN113940957A (en) * | 2021-12-02 | 2022-01-18 | 张鹏 | Formula for treating rhinitis disease |
Non-Patent Citations (5)
| Title |
|---|
| 吴正红等主编: "《药剂学》", 30 April 2020, 北京：中国医药科技出版社, pages: 436 - 438 * |
| 周长征等主编: "《全国中医药行业高等教育十四五规划教材 中药制药工程原理与设备 新世纪第5版》", 30 June 2021, 北京：中国中医药出版社, pages: 73 - 75 * |
| 汪河滨等: "甘草黄酮提取方法及抗氧化活性研究", 《时珍国医国药》, vol. 19, no. 9, 20 September 2008 (2008-09-20), pages 2106 - 2107 * |
| 王笃政等: "微波-超声波协同萃取技术在中药有效成分提取中的研究进展", 《化工中间体》, vol. 8, no. 05, 15 May 2011 (2011-05-15), pages 5 - 9 * |
| 黄晓梅等: "野菊花黄色素提取分离研究进展", 《亚太传统医药》, vol. 4, no. 12, 31 December 2008 (2008-12-31), pages 20 - 21 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1899535A (en) | Method for preparing dermopathic blood toxic capsule | |
| CN101721527B (en) | Traditional Chinese medicine jewelry cream and preparation method thereof | |
| CN108403937A (en) | It is a kind of to treat dermopathic external traditional Chinese medicine ointment and preparation method thereof | |
| KR20100079858A (en) | The new medicine for skin disease composed of mineral and medical herbs | |
| CN112107609B (en) | Application of Jingu lotus preparation in preparing medicine for treating chalazion | |
| CN106581439A (en) | Traditional Chinese medicine composition for treating wounds, diabetic feet and skin ulceration, and preparation method thereof | |
| CN105213256A (en) | A kind of Shu Min dispels red toner/smoothing toner and preparation method thereof | |
| CN105616679A (en) | Traditional Chinese medicine preparation with effects of nourishing blood and tranquilization and preparation method therefor | |
| CN117599012A (en) | Preparation method of nose comfort tablet | |
| CN103599409B (en) | One treats prosopalgic Chinese medicine composition | |
| CN102397341A (en) | Traditional Chinese medicine for treating oxyhepatitis | |
| CN106860509B (en) | Production process of carpet bugle capsule | |
| CN103417632A (en) | Compound essence for treating chronic rhinitis and extraction process thereof | |
| CN105521437A (en) | Spider and emei pueraria flower hemorrhoid-treating gel and preparation method thereof | |
| CN109125703A (en) | A kind of pharmaceutical composition and preparation method thereof for treating vaginitis | |
| CN103340967B (en) | Traditional Chinese medicine composition for treating aphtha and preparation method thereof | |
| CN104622924B (en) | A kind of medicine and its production technology for treating rhinitis | |
| CN101259188B (en) | Traditional Chinese medicine for treating chronic kidney diseases and preparation method thereof | |
| CN1247215C (en) | Medicine for treating mouth mucous ulcer | |
| CN106853193A (en) | It is a kind of to treat Chinese medicine of rheumatoid arthritis and preparation method thereof | |
| CN111956749A (en) | Medicine for treating and preventing gout and preparation method thereof | |
| CN1449802A (en) | Traditional Chinese medicine for treating arthralgia and preparation process thereof | |
| CN116726111A (en) | External medicine for treating traumatic injury | |
| CN105106590A (en) | Medicine for treating allergic rhinitis | |
| CN114272326A (en) | Composition for treating snake and insect bites |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |